Among people with a previous heart attack or stroke, or who are at high risk for one, a daily oral medication may offer an effective alternative to injections of PCSK9 inhibitors to lower low-density ...

In late-stage studies, Merck & Co.’s PCSK9-targeted pill achieved low-density lipoprotein cholesterol (LDL-C) reductions similar to those observed with existing injectables. The results from two phase ...

Adding the injectable PCSK9 inhibitor evolocumab — sold as Repatha — to a cholesterol-lowering treatment regimen was found to reduce the risk of a first-time major cardiovascular event among adults ...

For some people with high cholesterol, making lifestyle changes and taking routine statin medications may not be sufficient to help them reach their target cholesterol levels. For these patients, a ...

Oct 16 (Reuters) - A new type of cholesterol drug being developed by Regeneron Pharmaceuticals Inc and Sanofi SA, when used by itself, cut levels of "bad" LDL cholesterol almost in half in the first ...

LONDON, Nov 18 (Reuters) - Amgen's new injectable cholesterol drug Repatha has been turned down for use on Britain's state health service, underscoring a worldwide debate about the value of such ...

Having high cholesterol in the blood can lead to a buildup called “plaque” on the walls of the arteries, raising the risk of cardiovascular disease. - Mohammed Haneefa Nizamudeen/iStockphoto/Getty ...

(CNN) — For some people with high cholesterol, making lifestyle changes and taking routine statin medications may not be sufficient to help them reach their target cholesterol levels. For these ...

For many people living with stubbornly high cholesterol, lifestyle changes and statin therapy can only go so far. A recent study published in JAMA offers encouraging early evidence that a new oral ...